Rize Oncology Inc. (OTCPK: RZON.F)
Health Care · Pharmaceuticals · CA
$—
— today · — 1Y
Rize Oncology Inc. (OTCPK: RZON.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $12.12M.
trading between 0.00 and 0.16.
Tweenvest scores Rize Oncology Inc. across four factors: quality 26/100. Its strongest factor is quality.
RZON.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.12M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $0.16
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 75.74M
- Employees
- —
- Next earnings
- —
About Rize Oncology Inc.
GeneTether Therapeutics Inc., a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases. The company was founded in 2018 and is based in Kelowna, Canada.
- Founded
- 2018
- Listed since
- Mar 30, 2022
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.